Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.9379 -0.0176 (-1.84%)
Delayed Quote Updated: 11:09 AM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
News headline image
Ocugen (OCGN) Q3 2024 Earnings Call Transcript ↗
OCGN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET 
From Ocugen
Via GlobeNewswire
News headline image
A Preview Of Ocugen's Earnings ↗
 
Via Benzinga
News headline image
Ocugen Secures $30 Million in Debt Funding
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
From Ocugen
Via GlobeNewswire
News headline image
Peering Into Ocugen's Recent Short Interest ↗
 
Via Benzinga
News headline image
Why Ocugen (OCGN) Stock Is Falling ↗
Ocugen shares are trading lower by 11% Thursday morning. The company announced the pricing of its public offering. 
Via Benzinga
News headline image
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
From Ocugen
Via GlobeNewswire
News headline image
Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
From Ocugen
Via GlobeNewswire
News headline image
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
News headline image
Ocugen (OCGN) Q2 2024 Earnings Call Transcript ↗
OCGN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
InvestorNewsBreaks – Ocugen Inc. (NASDAQ: OCGN) Closes on $35M Public Offering
Via Investor Brand Network
News headline image
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
News headline image
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid ↗
These two stocks could have vastly different long-term performances. 
Via The Motley Fool
News headline image
3 Penny Stocks That Could Turn $10K Into $100K in 3 Years ↗
Discover three high-potential penny stocks that could derive 10X returns in biotechnology, silver and oil and gas storage and transportation. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.